Infectious Diseases

Combating global infectious threats

Fighting Infectious Threats

SXR Laboratories has extensive experience in infectious disease trials, including antivirals, antibiotics, antifungals, and vaccines. We respond rapidly to emerging infectious threats and pandemics.

Research Areas

Viral infection trials (HIV, hepatitis, influenza)
Bacterial resistance studies
Tropical disease research
Hospital-acquired infections
Antimicrobial stewardship trials
Pandemic preparedness studies

Foundational Technologies & Key Targets

Molecular Targets

Viral Surface Proteins: Targeting spike protein of SARS-CoV-2, gp120 of HIV, and hemagglutinin of influenza for vaccine development and therapeutic antibodies.

Bacterial Cell Wall Components: Targeting peptidoglycan synthesis and other essential bacterial structures for novel antibiotics.

Viral Replication Machinery: Polymerases, proteases, and integrases essential for viral lifecycle.

Vaccine Technologies

mRNA Vaccines: Using messenger RNA to instruct cells to produce pathogen antigens, enabling rapid vaccine development (COVID-19). Viral Vector Vaccines: Employing harmless viruses (adenovirus) to deliver genetic code for pathogen antigens. Subunit/Recombinant Vaccines: Using purified protein components of pathogens. Conjugate Vaccines: Linking weak antigens to strong carriers to enhance immune response. Adjuvants: Immune-boosting compounds added to enhance vaccine efficacy.

Therapeutic Approaches

Broadly Neutralizing Antibodies (bnAbs): Engineered antibodies targeting conserved regions across pathogen variants, particularly for HIV and influenza. Antivirals: Small molecules and biologics targeting viral replication. Gene Therapy Applications: Using CRISPR for rapid diagnostic development and creating HIV-resistant cells by knocking out CCR5 co-receptor.

Global Capabilities

Our global network enables rapid trial initiation in endemic regions and diverse populations. We maintain expertise in complex infectious disease protocols and biosafety requirements.

Integrated Research Excellence

Infectious disease research requires rapid, coordinated response across all research functions. Clinical Trials Management enables swift study activation with biosafety protocols and global site networks. Regulatory Affairs expedites emergency use authorizations and fast-track designations critical for outbreak response. Data Management implements real-time data collection systems for epidemic surveillance, while Biostatistics applies adaptive designs for rapid efficacy assessment. Quality Assurance ensures compliance with biosafety standards, and Medical Writing produces rapid reports for public health authorities and regulatory submissions.